Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alaunos Therapeutics, Inc.ZIOP · Entity 8339 | EVP, GM Gene Therapy | March 04, 2021 | March 08, 2021 |
| enGene Therapeutics Inc.ENGN · Entity 6638 | Chief Development Officer | January 30, 2026 | February 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alaunos Therapeutics, Inc.
Report date March 04, 2021 · Filed March 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 231,016 |
Reported balance
After 2021-03-04 transaction · row 1
1 source rowRow 1 · 2021-03-04 · Grant · Acquired 31,500 · Balance 231,016 F1: 7,875 shares shall vest on each of 12/31/2021, 12/31/2022, 12/31/2023 and 12/31/2024. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.31 · Expires 2031-03-04 | Direct | 236,250 |
Reported balance
After 2021-03-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-03-04 · Grant · Acquired 236,250 · Balance 236,250 F2: 1/16th of the shares underlying this option will vest in equal quarterly installments commencing one quarterly period after 12/31/2020. |
Filing footnotes · ownership attribution and instrument terms
F1: 7,875 shares shall vest on each of 12/31/2021, 12/31/2022, 12/31/2023 and 12/31/2024.
F2: 1/16th of the shares underlying this option will vest in equal quarterly installments commencing one quarterly period after 12/31/2020.
enGene Therapeutics Inc.
Report date January 30, 2026 · Filed February 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.53 · Expires 2036-01-30 | Direct | 195,000 |
Reported balance
After 2026-01-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-30 · Grant · Acquired 195,000 · Balance 195,000 F1: This option vests monthly in substantially equal amounts for 48 months, subject to the reporting person's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests monthly in substantially equal amounts for 48 months, subject to the reporting person's continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 30, 2026 Filed Feb 3, 2026 16:05 UTC | enGene Therapeutics Inc. ENGN · Entity 6638 | GrantStock Option (Right to Buy) · Derivative | 195,000 | $0.00 Strike: $9.53 | $0.00 |
DisclosureSEC source: 0000929638-26-000477 · form4.xml · derivative · entry 1 Buck Jill · CIK 0001780426 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,000 Underlying: Common Shares · 195,000 shares Expires 2036-01-30 F1 · derivative.exercise_date: This option vests monthly in substantially equal amounts for 48 months, subject to the reporting person's continued service. Read SEC document |
| July 08, 2025 Filed Jul 10, 2025 16:05 UTC | enGene Therapeutics Inc. ENGN · Entity 6638 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $3.83 | $0.00 |
DisclosureSEC source: 0000929638-25-002554 · form4.xml · derivative · entry 1 Buck Jill · CIK 0001780426 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Shares · 100,000 shares Expires 2035-07-08 F1 · derivative.exercise_date: This option vests monthly in substantially equal amounts for 48 months, subject to the reporting person's continued service. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:30 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantEmployee Stock Option (right to buy) · Derivative | 236,250 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001209191-21-018632 · doc4.xml · derivative · entry 2 Buck Jill · CIK 0001780426 · EVP, GM Gene Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,250 Underlying: Common Stock · 236,250 shares Expires 2031-03-04 F2 · derivative.exercise_date: 1/16th of the shares underlying this option will vest in equal quarterly installments commencing one quarterly period after 12/31/2020. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:30 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantCommon Stock | 31,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018632 · doc4.xml · nonDerivative · entry 1 Buck Jill · CIK 0001780426 · EVP, GM Gene Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,016 F1 · shares: 7,875 shares shall vest on each of 12/31/2021, 12/31/2022, 12/31/2023 and 12/31/2024. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 21:35 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | SaleCommon Stock | 27,894 | $3.12 | $87,029.28 |
DisclosureSEC source: 0001209191-21-003245 · doc4.xml · nonDerivative · entry 1 Buck Jill · CIK 0001780426 · EVP, GM Gene Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,516 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to satisfy withholding tax obligations upon the vesting of restricted stock grants. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.035 to $3.205, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:44 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantEmployee Stock Option (right to buy) · Derivative | 82,600 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0001209191-20-005778 · doc4.xml · derivative · entry 2 Buck Jill · CIK 0001780426 · EVP, GM Gene Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,600 Underlying: Common Stock · 82,600 shares Expires 2030-01-29 F2 · derivative.exercise_date: 1/12th of the shares underlying this option will vest in equal quarterly installments commencing one quarterly period after 12/31/2019. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:44 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantCommon Stock | 53,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-005778 · doc4.xml · nonDerivative · entry 1 Buck Jill · CIK 0001780426 · EVP, GM Gene Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,410 F1 · shares: 17,900 shares shall vest on each of 12/31/2020, 12/31/2021 and 12/31/2022. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 22:04 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | SaleCommon Stock | 27,923 | $4.55 | $127,049.65 |
DisclosureSEC source: 0001209191-20-001167 · doc4.xml · nonDerivative · entry 1 Buck Jill · CIK 0001780426 · EVP, GM Gene Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,710 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to satisfy withholding tax obligations upon the vesting of restricted stock grants. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.46 to $4.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.